About JCCT
JCCT is a company based in Lenexa (United States) founded in 2005 by Casey Johnson, Mazen Zari, and Nathan Arthur. JCCT offers products and services including Clinical Trial Services and Vaccine Trials. JCCT operates in a competitive market with competitors including Medpace, Lambda Therapeutic, Dhiti Life Sciences, Diacrin and Ascada Research, among others.
- Headquarter Lenexa, United States
- Founders Casey Johnson, Mazen Zari, Nathan Arthur
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of JCCT
JCCT offers a comprehensive portfolio of products and services, including Clinical Trial Services and Vaccine Trials.
Conducts studies for new medical treatments and participant compensation.
Tests vaccines for diseases like norovirus and influenza.
People of JCCT
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of JCCT
- Total Funding Total Funding
- Total Rounds 1
- Last Round Last Round
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2023 | Amount | Private Equity Round - JCCT | Valuation | FFL Partners |
|
Investors in JCCT
JCCT has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include FFL Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Lower middle market investments are targeted by FFL Partners.
|
Founded Year | Domain | Location |
Investments & Acquisitions by JCCT
Financial Statements - JCCT
Jcct Comparisons
Competitors of JCCT
JCCT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Medpace, Lambda Therapeutic, Dhiti Life Sciences, Diacrin and Ascada Research, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
A range of clinical research services is offered by Medpace.
|
|
| domain | founded_year | HQ Location |
CRO with operations in India, US, Poland, Canada and UK. Winner of Frost & Sullivan 'CRO of the Year' - 2010
|
|
| domain | founded_year | HQ Location |
Biotechnology company offering in vitro diagnostic products for healthcare sector
|
|
| domain | founded_year | HQ Location |
Educational programs are provided by Diacrin since 1989.
|
|
| domain | founded_year | HQ Location |
Performs clinical research trials to evaluate investigational drugs and devices.
|
Latest news on Jcct
Frequently Asked Questions about JCCT
JCCT was founded in 2005 and raised its 1st funding round 18 years after it was founded.
JCCT is headquartered in Lenexa, United States. It is registered at Lenexa, Kansas, United States.
Mazen Zari is the current CEO of JCCT. They have also founded this company.
JCCT, established in 2005, excels in providing healthcare solutions, biopharma outsourcing, cro, clinical development, and full service. CRO focused on early end stage clinical trial services. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
JCCT's top competitors include Medpace, Lambda Therapeutic and Dhiti Life Sciences.
JCCT offers Clinical Trial Services and Vaccine Trials.
JCCT has 1 investor. Key investors include FFL Partners.